Centromeric breakage and highly rearranged chromosome derivatives associated with mutations ofTP53 are common in therapy-related MDS and AML after therapy with alkylating agents: An M-FISH study

This publication has 36 references indexed in Scilit:

• Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation
  Blood, 2004
• Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia
  Leukemia, 2003
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
  Blood, 2002
• Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy‐related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents
  Genes, Chromosomes and Cancer, 2001
• Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
  Journal of Clinical Oncology, 2001
• Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere
  Leukemia, 2000
• Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome
  Genes, Chromosomes and Cancer, 1999
• The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
  Blood, 1998
• Tumor-suppressor p53: implications for tumor development and prognosis.
  Journal of Clinical Oncology, 1998
• Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocvtic leukemia (sANLL)
  European Journal of Haematology, 1991